RxDoctor Payments Data

Tommy Curtis, NP

Nurse Practitioner · Chatsworth, GANPI 1134546831

Payments from drug & device makers

$3,431in general payments, 2019–2025

Across 163 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$433
  • Amgen$403
  • Pfizer$325
  • Sanofi-aventis U.S. LLC$311
  • Bayer$242
  • Lilly USA, LLC$192
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$3,40699%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,431 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$54,589
Medicare patients
412
Services billed
1,677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$46,631
OzempicSemaglutide32$37,299
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$25,067
FarxigaDapagliflozin Propanediol18$18,987
TrulicityDulaglutide13$17,661
JardianceEmpagliflozin14$14,280
Albuterol Sulfate HfaAlbuterol Sulfate216$6,279
SymbicortBudesonide/Formoterol Fumarate21$4,740
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,214
Cefdinir109$1,617
Levothyroxine Sodium160$1,525
Rosuvastatin Calcium123$1,434
PaxlovidNirmatrelvir/Ritonavir16$1,367
Ventolin HfaAlbuterol Sulfate24$1,307
Gabapentin92$1,294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$325$47,99855 claims
Novo NordiskOzempic$132$37,29932 claims
GSKTrelegy Ellipta$170$25,06731 claims
AstraZenecaFarxiga, Symbicort$128$23,72639 claims
Lilly USA, LLCTrulicity$192$17,66113 claims
Boehringer IngelheimJardiance$81$14,28014 claims
AbbVieSynthroid$433$1,13921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Chatsworth

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →